Skip to content

Clinical Efficacy of 0.75% Boric Acid Gel in Chronic Periodontitis

Clinical Efficacy of Subgingivally Delivered 0.75% Boric Acid Gel As An Adjunct to Mechanotherapy in Chronic Periodontitis: A Randomized Controlled Clinical Trial

Status
Completed
Phases
Phase 2Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02903108
Enrollment
39
Registered
2016-09-16
Start date
2015-05-31
Completion date
2015-10-31
Last updated
2016-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Periodontitis

Brief summary

The purpose of the present study was to evaluate the effects of subgingival delivery of boric acid gel as an adjunct to scaling and root planing in chronic periodontitis (CP) patients.

Detailed description

Background: The purpose of this double-masked, randomized, controlled clinical trial was to evaluate the effects of subgingival delivery of boric acid gel as an adjunct to scaling and root planing (SRP) on clinical and radiographic parameters and compare this method with SRP plus placebo gel alone in with chronic periodontitis (CP) patients. Methods: Thirty nine systemically healthy patients with CP are included in this study. They were divided into two groups: 1) SRP + 0.75% Boric acid gel (BA group); 2) SRP + Placebo gel (Placebo group). At baseline, 3 month, and 6 months after treatment, clinical measurements, including plaque index (PI), modified sulcus bleeding index (mSBI), probing depth (PD), clinical attachment level (CAL) and radiographic parameters intrabony defect depth (IBD), percentage change in radiographic defect depth reduction (DDR%) were assessed.

Interventions

DRUGSRP plus boric acid gel

SRP followed by 0.75% boric acid placement into intrabony defect

SRP followed by placebo gel placement into intrabony defect

Sponsors

Government Dental College and Research Institute, Bangalore
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
25 Years to 55 Years
Healthy volunteers
Yes

Inclusion criteria

* Systemically healthy with deep pockets (PD of ≥5mm or CAL ≥4mm) and vertical bone loss ≥3 mm on intraoral periapical radiographs * Patients with ≥20 teeth with no history of periodontal therapy in the preceding 6 months nor under any antibiotic therapy

Exclusion criteria

* Patients on systemic boron therapy * Known or suspected allergy to boron supplementation * Patients with aggressive periodontitis * Tobacco use in any form, smokers, alcoholics * Immunocompromised and systemically unhealthy patients * Pregnant or lactating females

Design outcomes

Primary

MeasureTime frameDescription
Defect depth reduction (%)Change from baseline to 6 monthsassessed in percentage

Secondary

MeasureTime frameDescription
probing depth (mm)Change from baseline to 6 monthsmeasured in mm
clinical attachment level (mm)Change from baseline to 6 monthsmeasured in mm
modified sulcus bleeding indexChange from baseline to 6 monthsscale from 0-3
plaque indexChange from baseline to 6 monthsscale from 0-3

Countries

India

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026